Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Autoimmune Disorders

Free Subscription 13.04.2026 3 Ann Neurol 1 Brain 1 Curr Opin Immunol 1 Intern Med 3 J Neuroimmunol 4 J Neurol 2 Mult Scler 4 N Engl J Med 1 Nat Rev Neurol 5 Neurology 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. GERNERT JA, Bartos LM, Christmann T, Zausinger H, et al
   Hyperreflective Foci in the Inner Nuclear Layer: Proof-of-Concept for an Optical Coherence Tomography Derived Microglia-Related Marker in Multiple Sclerosis.
   Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78215.
   PubMed         Abstract available
   
   
2. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
   Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".
   Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78222.
   PubMed        
   
   
3. COPELAND TP
   Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.
   Ann Neurol. 2026 Apr 7. doi: 10.1002/ana.78218.
   PubMed        
   
   

   
   Brain

4. AGUZZI EA, Desai RA, Yang Z, Davies AL, et al
   A cause and protective treatment for acute and progressive disability and grey matter atrophy.
   Brain. 2026;149:1144-1152.
   PubMed         Abstract available
   
   

   
   Curr Opin Immunol

5. KUMAR S, Ponzar N, Pozzi N
   beta(2)-Glycoprotein I: structure, mechanisms of autoantibody recognition, and polymorphisms.
   Curr Opin Immunol. 2026;100:102771.
   PubMed         Abstract available
   
   

   
   Intern Med

6. IWAMOTO Y, Komi M, Fushimi Y, Murata Y, et al
   A Case of Autoimmune Polyendocrine Syndrome Type 3C with Warm-type Autoimmune Hemolytic Anemia which Developed during Treatment for Hashimoto's Thyroiditis.
   Intern Med. 2026 Apr 7. doi: 10.2169/internalmedicine.6632.
   PubMed         Abstract available
   
   

   
   J Neuroimmunol

7. PITTER D, Trahair E, Ayele F, Hutto SK, et al
   Systemic and neurologic autoimmune disorders and antibody seropositivity associated with neurosarcoidosis.
   J Neuroimmunol. 2026;417:578929.
   PubMed         Abstract available
   
   
8. CHUNG HY, Shin HY, Park HJ, Kim GJ, et al
   Germinal centers are associated with poor prognosis in patients with thymoma-associated myasthenia gravis.
   J Neuroimmunol. 2026;417:578926.
   PubMed         Abstract available
   
   
9. KHEDR EM, Haridy NA, El-Deen HB, Abdelwarith A, et al
   Tracking the invisible: Impact of disease-modifying therapies on serum neurofilament light chain and clinical outcomes in treatment-naive multiple sclerosis.
   J Neuroimmunol. 2026;417:578928.
   PubMed         Abstract available
   
   

   
   J Neurol

10. HEGEN H, Fottinger F, Walde J, Berek K, et al
    The role of age in choosing high-efficacy treatment for multiple sclerosis: an Austrian MS Database study.
    J Neurol. 2026;273:262.
    PubMed         Abstract available
    
    
11. JARIUS S, Ruprecht K, Metz I, Konig FB, et al
    An autoantibody signature predictive for multiple sclerosis: evidence at the protein level and association with histopathological lesion types.
    J Neurol. 2026;273:257.
    PubMed         Abstract available
    
    
12. GLEISNER N, Meda F, Johnsson M, Rosenstein I, et al
    Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barre syndrome: a possible prognostic biomarker for disability at 12 months.
    J Neurol. 2026;273:253.
    PubMed         Abstract available
    
    
13. ZIVADINOV R, Semy M, Bartnik A, Hildesheim FE, et al
    Dura mater enhancement on 3T MRI is associated with cortical lesion burden in multiple sclerosis.
    J Neurol. 2026;273:251.
    PubMed         Abstract available
    
    

    
    Mult Scler

14. GHAJARZADEH M, Mowry EM, Fitzgerald KC, Nourbakhsh B, et al
    Cardiovascular comorbidities are associated with cross-sectional and longitudinal measures of multiple sclerosis fatigue.
    Mult Scler. 2026 Apr 5:13524585261438014. doi: 10.1177/13524585261438014.
    PubMed         Abstract available
    
    
15. PIERRET C, Androdias G, Lebrun-Frenay C, Vukusic S, et al
    Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.
    Mult Scler. 2026 Apr 5:13524585261437966. doi: 10.1177/13524585261437966.
    PubMed         Abstract available
    
    

    
    N Engl J Med

16. KUTER DJ, Miura K, Patriarca A, Pulanic D, et al
    A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.
    N Engl J Med. 2026;394:1388-1398.
    PubMed         Abstract available
    
    
17. XIONG H, Li R, Shi J
    CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. Reply.
    N Engl J Med. 2026;394:1455.
    PubMed        
    
    
18. MURRAY JA, Husby S
    Celiac Disease.
    N Engl J Med. 2026;394:1421-1429.
    PubMed         Abstract available
    
    
19. YANG S, Lu Y
    CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.
    N Engl J Med. 2026;394:1455.
    PubMed        
    
    

    
    Nat Rev Neurol

20. FYFE I
    Skull bone marrow changes in multiple sclerosis.
    Nat Rev Neurol. 2026 Apr 9. doi: 10.1038/s41582-026-01207.
    PubMed        
    
    

    
    Neurology

21. REMIJN-NELISSEN L, Bakker WR, van den Hout WB, van Gelder T, et al
    Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
    Neurology. 2026;106:e214865.
    PubMed         Abstract available
    
    
22. REMIJN-NELISSEN L, Bakker WR, van Gelder T, Moes DJAR, et al
    Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
    Neurology. 2026;106:e214715.
    PubMed         Abstract available
    
    
23. PATEL AN, Kesselheim AS, Rome BN
    Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.
    Neurology. 2026;106:e214834.
    PubMed         Abstract available
    
    
24. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214917.
    PubMed        
    
    
25. BOURDETTE D, Hartung DM
    Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties.
    Neurology. 2026;106:e214920.
    PubMed        
    
    

    
    PLoS One

26. DELLBRUGGE F, Loges S, Henjes N, Wedemeyer H, et al
    Comparative evaluation of immunoserological detection of F-actin antibodies.
    PLoS One. 2026;21:e0345250.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum